-
公开(公告)号：US11365209B2
公开(公告)日：2022-06-21
申请号：US16938730
申请日：2020-07-24
IPC分类号： C07F9/6558
摘要： The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y12 receptor antagonist.
-
![Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide](/abs-image/US/2022/05/24/US11339148B2/abs.jpg.150x150.jpg)
公开(公告)号：US11339148B2
公开(公告)日：2022-05-24
申请号：US16964885
申请日：2019-01-25
发明人： Philippe Guerry , Markus Von Raumer
IPC分类号： C07D413/14
摘要： The invention relates to crystalline forms of (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide; processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CXCR7 receptor modulators.
-
公开(公告)号：US11306058B2
公开(公告)日：2022-04-19
申请号：US16618036
申请日：2018-05-31
发明人： Vitor Oliveira , Ivan Pogorelic , Jean-Paul Roduit
IPC分类号： C07D211/40 , C07D211/46 , A61K9/48 , A61P3/06 , A61P43/00 , A61P25/00 , A61P35/00 , A61K31/445
摘要： The invention relates to a crystalline form of [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)-piperidine-3,4,5-triol, processes for the preparation thereof, pharmaceutical compositions containing such a crystalline form, and its use as a medicament, especially as glycolipid biosynthesis inhibitor.
-
公开(公告)号：US10752620B2
公开(公告)日：2020-08-25
申请号：US16320906
申请日：2017-07-27
发明人： Hamed Aissaoui , Philippe Guerry , Francois Lehembre , Julien Pothier , Laetitia Pouzol , Sylvia Richard-Bildstein , Shuguang Yuan
IPC分类号： C07D413/14 , C07D401/12 , A61P35/00 , C07D401/14 , C07D413/12 , C07D417/14
摘要： The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
-
公开(公告)号：US10351560B2
公开(公告)日：2019-07-16
申请号：US15759710
申请日：2016-09-14
发明人： Hamed Aissaoui , Christoph Boss , Patrick Bouis , Julien Hazemann , Romain Siegrist , Markus Von Raumer
IPC分类号： C07D471/04 , A61P37/02 , A61P37/08
摘要： The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
-
![1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives](/abs-image/US/2019/04/16/US10259807B2/abs.jpg.150x150.jpg)
公开(公告)号：US10259807B2
公开(公告)日：2019-04-16
申请号：US14906882
申请日：2014-07-21
发明人： Eva Caroff , Emmanuel Meyer
IPC分类号： C07D417/14
摘要： The invention relates to compounds of Formula (I) wherein X, Y, R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.
-
公开(公告)号：US10246426B2
公开(公告)日：2019-04-02
申请号：US15510980
申请日：2015-09-14
IPC分类号： C07D249/04 , C07D403/12 , C07D401/12 , C07D405/12 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/06 , C07D471/04
摘要： The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
-
公开(公告)号：US10065929B2
公开(公告)日：2018-09-04
申请号：US15847611
申请日：2017-12-19
IPC分类号： A61K31/4155 , A61K31/4439 , A61K31/415 , A61P3/10 , A61P9/00 , A61P15/00 , C07D231/40 , C07D403/06 , C07D471/04 , C07D413/12 , C07D405/12 , C07D401/12 , C07D401/06 , C07D405/14 , C07D401/14 , C07D403/12
摘要： The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
-
公开(公告)号：US09879006B2
公开(公告)日：2018-01-30
申请号：US15125018
申请日：2015-03-16
IPC分类号： C07D401/12 , C07D401/14 , C07D471/04
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
-
公开(公告)号：US20170305897A1
公开(公告)日：2017-10-26
申请号：US15644547
申请日：2017-07-07
发明人： Christoph BOSS , Christine BROTSCHI , Markus GUDE , Bibia HEIDMANN , Thierry SIFFERLEN , Jodi T. Williams
IPC分类号： C07D417/14 , C07D401/14 , C07D403/04 , C07D403/14
CPC分类号： C07D417/14 , C07D401/14 , C07D403/04 , C07D403/14
摘要： The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
-
-
-
-
-
-
-
-
-
搜索结果
119 条记录 (耗时 0.045 秒)
